Targeting the pathology, not the pathogen

101 Therapeutics is creating a paradigm shift in how we think about and treat infectious diseases.

Learn more

Our groundbreaking approach

101 Therapeutics has developed the first-ever targeted glucocorticoid with all of the potency of steroids and none of the systemic toxicities. By targeting the host immune system rather than the pathogen itself, we can effectively treat a multitude of infectious diseases, whether viral, parasitic, or bacterial.


We are able to target key cells that drive inflammation by zeroing in on a unique receptor.


Our drug remains fully intact and inactive until it reaches its target for activation. Our first-in-human Phase I clinical trial proved never-before-seen safety for a drug of this class.


Because our drug is pathogen-agnostic, it can be used for a host of infectious diseases.

Our Science

Get in touch with us today

Your message has been sent
We will get back to you as soon as possible
Thank you!
Error when submitting the form
Try submitting the form again
Try again